ACM
PTCT icon

Ayer Capital Management’s PTC Therapeutics PTCT Stock Holding History

Ayer Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-262,069
Closed -$4.45M – 1
2013
Q4 		$4.45M Sell
262,069
-154,597
-37% -$2.72M 100% 1
2013
Q3 		$7.15M Buy
+416,666
New +$7.24M 38.92% 2

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ayer Capital Management's PTCT Position: Q1 2014 in Review

Ayer Capital Management sold out of PTC Therapeutics (PTCT) in Q1 2014, closing a stake of 262,069 shares — an estimated $4.45M sold.

Ayer Capital Management first reported a position in PTCT in Q3 2013 and held it in 2 quarters. The position peaked at $7.15M in Q3 2013. 65 funds tracked by Wall St. Rank hold PTCT as of Q1 2014.

  • Ayer Capital Management reported no remaining PTC Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Ayer Capital Management sold 262,069 PTC Therapeutics shares in Q1 2014, an estimated $4.45M.
  • Ayer Capital Management first reported a position in PTC Therapeutics in Q3 2013 and held it in 2 quarters.
  • Ayer Capital Management's PTC Therapeutics position peaked at $7.15M in Q3 2013.
  • 65 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2014.

Based on Ayer Capital Management's 13F filing for Q1 2014.